Breathe Well Live Well
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg; Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Drug: Umeclidinium 62.5 mcg; Device: Placebo ELLIPTA inahler; Drug: Albuterol/Salbutamol
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Bel Marra Health |
Asthma patients face higher risk of pulmonary embolism, deep vein thrombosis
Bel Marra Health Asthma patients face higher risk of pulmonary embolism and deep vein thrombosis. The findings were published in the European Respiratory Journal. Researchers looked at moderate to severe asthma sufferers and their risk of pulmonary embolism and deep … |
View full post on asthma – Google News
| Related Articles |
Republished: The clinical spectrum of pulmonary aspergillosis.
Postgrad Med J. 2015 Jul;91(1077):403-10
Authors: Kosmidis C, Denning DW
Abstract
The clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids. A high index of suspicion is required in patients without the classical risk factors as early presentation is usually silent and non-specific, pyrexia uncommon and timely treatment is crucial for survival. Invasive aspergillosis has also been diagnosed in normal hosts after massive exposure to fungal spores. Chronic pulmonary aspergillosis affects patients without obvious immune compromise, but with an underlying lung condition such as COPD or sarcoidosis, prior or concurrent TB or non-tuberculous mycobacterial disease. Aspergillus bronchitis may be responsible for persistent respiratory symptoms in patients with Aspergillus detected repeatedly in sputum without evidence of parenchymal Aspergillus disease, especially in patients with bronchiectasis and cystic fibrosis. Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated. Changes in the classification of Aspergillus allergic lung disease have been proposed recently. Cases of extrinsic allergic alveolitis and chronic pulmonary aspergillosis have been observed after Aspergillus exposure. Asymptomatic colonisation of the respiratory tract needs close monitoring as it can lead to clinical disease especially with ongoing immunosuppression. The various syndromes should be viewed as a semicontinuous spectrum of disease and one form may evolve into another depending on the degree of ongoing immunosuppression.
PMID: 26187954 [PubMed – in process]
View full post on pubmed: asthma
Conditions: Pulmonary Arteriovenous Malformations; Hereditary Hemorrhagic Telangiectasia; Asthma; COPD
Intervention: Other: Cardiopulmonary exercise test
Sponsor: Imperial College London
Not yet recruiting – verified April 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Marketed antagonists
Sponsor: Teva Pharmaceuticals Europe
Not yet recruiting – verified April 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Are the Diagnostic Criteria for Asthma-COPD Overlap Syndrome Appropriate in Biomass Smoke-Induced chronic obstructive pulmonary disease?
Arch Bronconeumol. 2015 Mar 19;
Authors: Golpe R, Pérez de Llano L
PMID: 25799499 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Conditions: Pulmonary Disease, Chronic Obstructive; Overweight
Interventions: Dietary Supplement: Resveratrol; Dietary Supplement: Placebo
Sponsors: Maastricht University Medical Center; The Netherlands Asthma Foundation; DSM Nutritional Products, Inc.
Not yet recruiting – verified September 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Interventions: Drug: Macitentan; Drug: Placebo
Sponsor: Actelion
Not yet recruiting – verified December 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Related Articles |
The Involvement of Phospholipases A 2 in Asthma and Chronic Obstructive Pulmonary Disease.
Mediators Inflamm. 2013;2013:793505
Authors: Pniewska E, Pawliczak R
Abstract
The increased morbidity, mortality, and ineffective treatment associated with the pathogenesis of chronic inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD) have generated much research interest. The key role is played by phospholipases from the A2 superfamily: enzymes which are involved in inflammation through participation in pro- and anti-inflammatory mediators production and have an impact on many immunocompetent cells. The 30 members of the A2 superfamily are divided into 7 groups. Their role in asthma and COPD has been studied in vitro and in vivo (animal models, cell cultures, and patients). This paper contains complete and updated information about the involvement of particular enzymes in the etiology and course of asthma and COPD.
PMID: 24089590 [PubMed – as supplied by publisher]
View full post on pubmed: asthma